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CASE STUDY
Iatrogenic Cushing syndrome 
and adrenal insufficiency during concomitant 
therapy with ritonavir and fluticasone
Narendranath Epperla1* and Fergus McKiernan2
Abstract 
Ritonavir is a potent inhibitor of the cytochrome P450 enzyme CYP3A4 and is subject to multiple drug–drug interac-
tions. This becomes especially important when the patient is also taking medications metabolized through CYP3A 
pathway as increased and potentially toxic drug levels may ensue. Herein we present one such interaction wherein a 
57 year old gentleman with human immunodeficiency virus (HIV) infection on highly active antiretroviral therapy that 
included ritonavir, had addition of fluticasone inhaler to his medication repertoire for treatment of chronic obstructive 
pulmonary disease. This resulted in severe osteoporosis, iatrogenic Cushing syndrome and adrenal insufficiency due 
to the potentiated systemic glucocorticoid effect of inhaled fluticasone by ritonavir. This case emphasizes the need for 
pharmacovigilance when managing patients on complex drug regimens for physicians treating HIV infected patients.
Keywords: Ritonavir, Fluticasone, Cytochrome P450, Human immunodeficiency virus
© 2015 Epperla and McKiernan. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made.
Background
Ritonavir is a potent inhibitor of the cytochrome P450 
enzyme CYP3A4 that can lead to multiple drug–drug 
interactions. Systemic complications resulting from 
inhaled corticosteroids like fluticasone are rare but when 
used concomitantly with ritonavir can lead to iatrogenic 
Cushing syndrome and adrenal suppression. It is impor-
tant to be aware of this interaction to avoid serious and 
potentially fatal complications. We report a case of iat-
rogenic Cushing syndrome, adrenal insufficiency and 
severe osteoporosis due to the potentiated systemic glu-
cocorticoid effect of inhaled fluticasone by ritonavir in a 
patient with human immunodeficiency virus (HIV).
Case presentation
A 57  year old Caucasian male with HIV infection since 
1986 was evaluated in 4/2010 for recurrent rib frac-
tures following trivial stresses such as coughing. His 
highly active antiretroviral therapy (HAART) since 2006 
consisted of lamivudine 150  mg twice daily, zidovudine 
300 mg twice daily and lopinavir–ritonavir 400–100 mg 
twice daily. Fluticasone/salmeterol 250/50  mcg one puff 
twice daily was introduced in 9/2007 for severe COPD. 
Other medical conditions included coronary artery 
disease, dyslipidemia and GERD treated with aspirin, 
clopidogrel, omeprazole, pravastatin and niacin. Physi-
cal examination showed centripetal adiposity, multiple 
ecchymoses and pronounced pink abdominal and ingui-
nal striae (Fig.  1). Weight had increased by 5  kg from 
baseline weight. There was palpable rib tenderness. The 
reminder of the physical examination was unremark-
able. Of note his AIDS clinician mistook his phenotypic 
changes to be those of AIDS related lipodystrophy. These 
same changes eluded his PCP.
Chest radiographs confirmed numerous rib fractures 
(Fig. 2). Lumbar and proximal femur bone mineral den-
sity (BMD) T-scores were −5.2 and −3.4 respectively. 
Complete blood count, renal and hepatic function, elec-
trolytes, calcium, phosphate, intact parathyroid hor-
mone, 25-OH-VitD, prolactin, serum and urine protein 
electrophoresis and serum free light chains were normal. 
His random morning serum cortisol was 0.5 mcg/dl (nor-
mal 4–24 mcg/dL) and 1  h after 250  mcg intravenous 
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cosyntropin stimulation was 7.1  mcg/dL (expected >20 
mcg/dL) consistent with adrenal insufficiency. A 24  h 
urine free cortisol was <7.2  mcg, late night salivary 
cortisol was <10  ng/dL (<100  ng/dL) and dehydroepi-
androsterone sulphate was <30 mcg/dL (40–310  mcg/
dL). Serum ACTH was 32 pg/mL (normal 0–46 pg/mL). 
A 24 h urinary synthetic glucocorticoid screen was only 
positive for a fluticasone 17-β-carboxylic acid value of 
243 pg/mL. Pituitary magnetic resonance imaging (MRI) 
was normal. Serum and 24-h urine N-telopeptides were 
19.2  nmol BCE (5.4–24  nmol BCE) and 23  nmol/mmol 
BCE (21–66  nmol/mmol BCE) respectively. Total and 
bone specific alkaline phosphatase were 73  IU/L (20–
71 IU/L) and 151 IU/L (40–125 IU/L) respectively.
The patient was diagnosed with iatrogenic Cushing 
syndrome and adrenal suppression secondary to the 
potentiated systemic glucocorticoid effect of inhaled 
fluticasone by ritonavir. Fluticasone was continued as 
the patient reported significant improvement in his 
COPD symptoms. Ritonavir boosted protease inhibitor 
therapy was discontinued and he was placed on Ralte-
gravir which is not known to inhibit CYP3A4. His HIV 
viral load continues to be undetectable and 2 years after 
change in antiretroviral therapy his CD4 count is 624. 
He was placed on physiological doses of hydrocortisone 
at 20 mg per day and has gradually tapered to 5 mg/day 
of hydrocortisone 1  year from presentation. His severe 
osteoporosis was treated with subcutaneous teriparatide, 
appropriate calcium and vitamin D supplementation and 
a physical therapy.
Serial basal and stimulated cortisol levels are reported 
in Table 1. His cushingoid features improved by 3 months 
(Fig.  3). One year after initiating osteoporosis treatment 
lumbar spine BMD improved from 0.530 to 0.932 gm/cm2 
(+75.8 %) and total hip BMD from 0.681 to 0.761 gm/cm2 
(+11.2 %). These BMD gains are significantly greater than 
those reported for lumbar spine (11 %) and total hip (5.2 %) 
in patients with glucocorticoid induced osteoporosis 
treated with teriparatide (Saag et al. 2009). Follow up BMD 
at the completion of teriparatide treatment is shown in 
Table 2 and Fig. 4. The patient has had no further fractures.
Discussion
A search of published English language literature using 
the keywords ritonavir, protease inhibitors, fluticasone, 
inhaled corticosteroids, Cushing’s syndrome and adre-
nal suppression revealed a total of 11 pediatric and 26 
adult cases of iatrogenic Cushing’s syndrome and adrenal 
suppression from concomitant fluticasone and ritonavir 
therapy. 3 of 24 adult cases were secondary to intranasal 
fluticasone preparations and rest was from inhaled fluti-
casone. Fluticasone dose ranged from 500 to 2000 mcg/
day in adult patients and 200–1000  mcg/day in pediat-
ric patients. Ritonavir in both low doses “boosted” and 
in high doses was associated with significant interaction 
(Table 3).
Fig. 1 Centripetal adiposity, multiple ecchymoses and pronounced 
pink abdominal and inguinal striae
Fig. 2 Chest X-ray showing numerous rib fractures
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Combination anti-retroviral therapy, particularly the 
introduction of protease inhibitors has revolutionized 
HIV therapy and changed once a fatal disease to a chronic 
condition (Palella et al. 1998). Ritonavir is a potent inhib-
itor of cytochrome P450 (CYP) 3A4 isozymes and sig-
nificantly increases the concentration of drugs primarily 
eliminated by CYP3A metabolism such as macrolides, 
azoles, protease inhibitors and corticosteroids (Hsu et al. 
1998; Von Moltke et  al. 1998). This property of ritona-
vir is used to therapeutic advantage in ritonavir boosted 
protease inhibitor regimens and has decreased the pill 
burden and treatment failures and improved compliance 
with therapy (Thompson et al. 2010).
With 30 % estimated prevalence of bronchial hyperac-
tivity (Poirier et al. 2001), HIV infected men who smoke 
are frequently exposed to inhaled corticosteroid therapy. 
To reduce airway inflammation treatment guidelines for 
asthma and chronic obstructive airway disease (COPD) 
recommend the routine use of inhaled corticosteroid 
alone or in combination with long acting bronchodila-
tors (National Asthma Education and Prevention Pro-
gram 2002; Vestbo et  al. 2013). Fluticasone is a potent 
glucocorticoid commonly used in reactive airway dis-
ease. Compared with other available inhaled steroids, 
it has high glucocorticoid receptor binding affinity, is 
highly lipophilic, a large volume of distribution (318  L) 
(Wuerthwein et al. 1992; Mackie et al. 1996) and a longer 
elimination half-life (t1/2 7–8  h). Less than 1  % of swal-
lowed fluticasone is bioavailable due to its high first pass 
metabolism and rapid metabolism in liver by CYP3A4 
enzyme system and conversion to inactive 17 B-carbox-
ylic acid derivative (Harding 1990). Concomitant use of 
fluticasone with potent CYP3A4 inhibitors such as rito-
navir can lead to systemic accumulation of fluticasone 
and suppression of hypothalamic pituitary adrenal (HPA) 
axis. Ritonavir increased the area under concentration–
time curve (AUC) of serum fluticasone by 350-fold in 
healthy volunteers (Laboratories 2006). For this reason 
manufactures and the FDA recommend against routine 
use of combination of ritonavir and fluticasone unless 
benefits outweigh risks.
Fluticasone has been reported to cause greater dose 
related adrenal suppression when compared with bude-
sonide, triamcinolone acetonide or beclomethasone 
dipropionate (Lipworth 1999) even in the absence of 
CYP3A4 inhibitors like ritonavir. In a recent meta-anal-
ysis of 732 subjects with asthma, fluticasone in small to 
medium doses (50–500 mcg/day) alone showed minimal 
effect on adrenal function (Masoli et al. 2006). In another 
prospective, non-randomized, open-label, cross sectional 
study, investigators found that patients taking high doses 
of fluticasone (>880 mcg per day) for longer duration had 
abnormal adrenal function (White et al. 2006).
Iatrogenic Cushing syndrome results from prolonged 
exposure to high doses of glucocorticoids. The vast 
majority of these cases result from administration of 
oral or parenteral glucocorticoids (Newell-Price et  al. 
2006). Typical features include weight gain, central obe-
sity, dorsocervical hump, moon face, facial plethora, thin 
skin, easy bruising, abdominal striae, hirsutism, proximal 
myopathy, osteopenia, glucose intolerance, hyperten-
sion, nephrolithiasis and psychiatric manifestations such 
as depression and psychosis (Newell-Price et  al. 2006). 
Osteoporosis is common and tends to involve trabecular 
Table 1 Basal and stimulated cortisol levels
Basal cortisol  
(mcg/dL)
1 h post ACTH cortisol 
level (mcg/dL)
At diagnosis 0.5 7.1
2 months 2.5 –
9 months 3.3 18
12 months 8.3 23.6
24 months 7 22.5
Fig. 3 Markedly improved abdominal and inguinal striae as well as 
the ecchymotic lesions
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bone resulting in an increased risk of fracture within 
3  months of daily exposure (van Staa et  al. 2000, 2002, 
2005).
Pituitary production of corticotropin (ACTH) will be 
suppressed by exogenous steroids, which leads to atrophy 
of the adrenal cortex and adrenal insufficiency. Diagnosis 
is confirmed by low early morning serum cortisol levels 
and subnormal response to standard ACTH stimulation 
test. An early morning serum cortisol levels <3 mcg/
dL (80  nmol/L) strongly suggests adrenal insufficiency, 
whereas levels >15 mcg/dL (415 nmol/L) predicts a nor-
mal response of serum cortisol to ACTH stimulation 
test (Hagg et al. 1987; Le Roux et al. 2002). Patients with 
low or equivocal serum cortisol levels in whom adrenal 
insufficiency is suspected should undergo standard or 
low dose synthetic ACTH (Cosyntropin) stimulation 
test. Suboptimal response to Cosyntropin stimulation 
test is diagnostic of adrenal insufficiency. Simultaneous 
measurement of plasma ACTH helps in differentiation 
of primary from secondary or tertiary adrenal insuf-
ficiency. ACTH levels tend to be higher than normal in 
primary adrenal insufficiency whereas low or low normal 
in patients with secondary and tertiary adrenal insuf-
ficiency. Corticotropin-releasing hormone (CRH) test 
further differentiate secondary from tertiary adrenal 
insufficiency (Schulte et al. 1984).
Human immunodeficiency virus associated lipodys-
trophy shares several morphological features and should 
be differentiated from Cushing Syndrome. Weight gain, 
central adiposity, dorsocervical hump, insulin resist-
ance, osteopenia, dyslipidemia are common and are 
associated with ART therapy (Lichtenstein 2005; Dube 
et  al. 2007; Carr and Cooper 1998). Presence of facial 
plethora, cutaneous striae, and proximal myopathy dif-
ferentiates it from Cushing syndrome and should prompt 
physicians to evaluate for HPA axis suppression. Sud-
den withdrawal of from steroid therapy has a poten-
tial to develop catastrophic adrenal crisis. Replacement 
with physiological doses of prednisone 5–7.5  mg a day, 
hydrocortisone 15–20 mg a day or equivalent should be 
initiated. Measurement of morning cortisol levels every 
4–6 weeks serves as screening test for recovery of adrenal 
function. Morning serum cortisol level less than 3 mcg/
dL indicates the need for continued replacement therapy, 
whereas a value greater than 20 mcg/dL indicates recov-
ered HPA axis. Patients with morning cortisol levels 
between 3 and 20 mcg/dL will need further studies like 
Cosyntropin stimulation test or overnight metyrapone 
Table 2 BMD improvement after  withdrawal of  ritonavir 
and treatment with teriparatide
BMD in gm/cm2 (T-score)
L-Spine Total hip (mean) Femoral neck (mean)
At diagnosis 0.530 (−5.7) 0.681 (−2.9) 0.589 (−3.7)
12 months 0.932 (−2.4) 0.761 (−2.4) 0.694 (−2.9)
24 months 1.065 (−1.3) 0.825 (−1.9) 0.734 (−2.6)
36 months 1.139 (−0.7) 0.867 (−1.6) 0.767 (−2.3)
Fig. 4 DXA trend after withdrawal of ritonavir and treatment with teriparatide along with depiction of improved trabecular bone scores
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Table 3 Review of literature and showing the cases of iatrogenic Cushing’s syndrome and adrenal suppression from con-
comitant fluticasone and ritonavir therapy
Authors Age RTV dose  
(mg/day)
ICS dose (mcg/day) Durationa Intervention
Mahlab-Guri and Asher (2011)
 Case 1 12 F 200 Fluticasone 200 6 months Fluticasone replaced by montelukast
 Case 2 55 F 200 Fluticasone 1000 3 weeks Fluticasone replaced by budesonide
 Case 3 65 F 200 Fluticasone 500 6 months Fluticasone discontinued
Kaviani et al. (2011)
 Case 1 60 M NA Fluticasone 1200 2 years Fluticasone discontinued
Kedem et al. (2010)
 Case 1 F NA NA UNK Fluticasone and budesonide discontinued
Ritonavir dose decreased
Samaras et al. (2005)
 Case 1 43 M 200 Fluticasone 500 2 years Fluticasone discontinued
 Case 2 43 M 100 Fluticasone 1000 18 months Fluticasone discontinued
 Case 3 53 M 200 Fluticasone 1000 2 years Fluticasone discontinued
 Case 4 49 M 200 Fluticasone 1000 6 weeks PI discontinued
 Case 5 43 M 200 Fluticasone 500 4 months Fluticasone discontinued
 Case 6 50 M 100 Fluticasone 1000 2 months Fluticasone discontinued
Nocent et al. (2004)
 Case 1 38 M NA Fluticasone 2000 1.5 months Fluticasone replaced with beclomethasone
Leitman et al. (2009)
 Case 1 49 M NA Fluticasone 1000 UNK Fluticasone dose reduced
Valin et al. (2009)
 Case 1 65 F NA Fluticasone 500 6 months Fluticasone discontinued
 Case 2 66 M NA Fluticasone 500 1 month Fluticasone discontinued
 Case 3 66 M NA Fluticasone 500 2 years Fluticasone discontinued
 Case 4 29 M NA Fluticasone 2000 1 month Fluticasone discontinued PI replaced with nelfinavir
Jinno and Goshima (2008)
 Case 1 60 M NA Fluticasone NA 18 months Fluticasone discontinued
Gillett et al. (2005)
 Case 1 27 F 200 Fluticasone 1000 10 weeks Fluticasone discontinued
Soldatos et al. (2005)
 Case 1 66 M 200 Fluticasone 1000 4 months Fluticasone dose decreased
 Case 2 66 M 200 Fluticasone 1000 6 months Fluticasone replaced with budesonide
Rouanet et al. (2003)
 Case 1 44 M 266.4 Fluticasone 2000 2 months Fluticasone discontinued
Gupta and Dubé (2002)
 Case 1 45 M 800 Fluticasone 880 5 months Fluticasone tapered
Clevenbergh et al. (2002)
 Case 1 33 M 200 Fluticasone 1000 5 months Fluticasone discontinued
Chen et al. (1999)
 Case 1 32 M Fluticasone 400 5 months Fluticasone discontinued
 Case 2 39 M Fluticasone 800 18 months Fluticasone discontinued
Hillebrand-Haverkort et al. (1999)
 Case 1 30 M 1200 Fluticasone 200 5 months RTV replaced by NVP
Arrington-sanders et al. (2006)
 Case 1 11.4 F 133 Fluticasone 220 Fluticasone and PI discontinued
 Case 2 20.9 M 100 Fluticasone 200 Fluticasone discontinued
 Case 3 16.8 M 200 Fluticasone 250 Stopped all medications
 Case 4 9.5 M 133 Fluticasone 220 Fluticasone discontinued
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test. It may take 9–12 months for the recovery of adrenal 
function (Hopkins and Leinung 2005).
In patients with iatrogenic Cushing syndrome and 
adrenal insufficiency secondary to the interaction 
between ritonavir and fluticasone available options 
include, replacing ritonavir with another antiretrovi-
ral agent, replacing fluticasone with another less potent 
steroid or leukotriene antagonists or long acting anticho-
linergic agent such as tiotropium. In the SPIRAL study, 
Raltegravir demonstrated the non-inferior efficacy and 
improved lipid profile when ritonavir boosted protease 
inhibitor therapy was replaced by Raltegravir (Martinez 
et al. 2010). The latter approach was taken in our patient 
with favourable outcome.
Conclusions
Despite the recommendations against concomitant use of 
fluticasone and ritonavir several reports of Cushing syn-
drome and adrenal suppression are being reported. We 
believe physicians treating HIV infected patients must 
be aware of potential interaction of antiretroviral therapy 
and drugs used to treat associated co-morbidities. When 
iatrogenic Cushing syndrome is suspected, prompt eval-
uation and discontinuation of offending medication will 
prevent potentially fatal complications.
Consent
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